Tyra Biosciences, Inc. (NASDAQ:TYRA) Stock Has Average Target Price of $47.20 According to Analysts

Shares of Tyra Biosciences, Inc. (NASDAQ:TYRA) have earned an average rating of “Moderate Buy” from the fifteen brokerages that are presently covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, eleven have assigned a buy recommendation and two have given a strong buy recommendation to the company. The average 1 year price target among brokers that have covered the stock in the last year is $47.20.

TYRA has been the topic of several recent research reports. Wedbush reaffirmed an “outperform” rating and issued a $53.00 price objective on shares of Tyra Biosciences in a research note on Thursday, September 10th. Oppenheimer reissued an “outperform” rating and issued a $40.00 target price (down from $50.00) on shares of Tyra Biosciences in a report on Tuesday, September 22nd. Raymond James Financial reissued a “strong-buy” rating and issued a $50.00 price objective on shares of Tyra Biosciences in a research note on Tuesday, October 6th. Weiss Ratings restated a “sell (d-)” rating on shares of Tyra Biosciences in a research report on Thursday, October 15th. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of Tyra Biosciences in a research report on Thursday, September 10th.

Institutional Investors Weigh In On Tyra Biosciences

Institutional investors have recently bought and sold shares of the business. Sterling Capital Management LLC lifted its position in shares of Tyra Biosciences by 843.4% in the third quarter. Sterling Capital Management LLC now owns 1,217 shares of the company’s stock valued at $27,000 after acquiring an additional 1,088 shares in the last quarter. Hilton Head Capital Partners LLC bought a new position in shares of Tyra Biosciences in the first quarter worth about $30,000. State of Wyoming bought a new stake in Tyra Biosciences during the 2nd quarter valued at approximately $76,000. Caitong International Asset Management Co. Ltd bought a new stake in Tyra Biosciences during the 4th quarter valued at approximately $79,000. Finally, Canada Pension Plan Investment Board bought a new position in Tyra Biosciences in the 2nd quarter worth approximately $230,000. Hedge funds and other institutional investors own 84.14% of the company’s stock.

Tyra Biosciences Price Performance

Tyra Biosciences stock opened at $20.45 on Tuesday. Tyra Biosciences has a one year low of $13.35 and a one year high of $40.65. The business’s fifty day moving average is $23.22 and its 200 day moving average is $28.83. The stock has a market capitalization of $1.22 billion, a PE ratio of -8.52 and a beta of 0.75.

Tyra Biosciences (NASDAQ:TYRA) last announced its quarterly earnings results on Tuesday, August 4th. The company reported ($0.69) EPS for the quarter, missing analysts’ consensus estimates of ($0.65) by ($0.04). As a group, sell-side analysts expect that Tyra Biosciences will post -2.68 EPS for the current fiscal year.

Tyra Biosciences Company Profile

Tyra Biosciences, Inc is a clinical-stage biotechnology company focused on developing precision medicines for patients with cancer and other diseases driven by fibroblast growth factor receptor (FGFR) abnormalities. The company uses its proprietary SNÅP platform to discover and design small-molecule therapies intended to selectively target FGFR alterations while addressing mechanisms of treatment resistance.

Tyra’s lead program, TYRA-300, is an oral, selective FGFR3 inhibitor being evaluated in clinical studies for FGFR3-altered urothelial cancer and other potential indications.